Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q deletion (del(5q)) with or without additional cytogenetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Komrokji, R. S., List, A. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684154/
https://www.ncbi.nlm.nih.gov/pubmed/26504152
http://dx.doi.org/10.1093/annonc/mdv488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684154/
https://www.ncbi.nlm.nih.gov/pubmed/26504152
http://dx.doi.org/10.1093/annonc/mdv488

Ejemplares similares